| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Pinostilbene targets multiple pathways. It is an effective enzyme inhibitor, showing potent inhibition of recombinant human CYP1B1 with IC50 and Ki values of 2100 nM and 900 nM, respectively, and CYP1A1 with a Ki value of 120 nM. It attenuates the phosphorylation of JNK and c-Jun triggered by 6-OHDA. Pinostilbene exhibits inhibitory effects on colon cancer cells and has protective effects against neurotoxicity. It also scavenges DPPH radicals with an IC50 of 47.1 μM.
|
|---|---|
| ln Vitro |
Normal colon cell proliferation is not significantly inhibited by pinosinbene (0–40 μM; 24–48 hours) [1]. When compared to control cells, pinostilbene (20 μM, 40 μM; 24 hours, 48 hours) significantly and dose-dependently increases the percentage of S phase cells in HCT116 and HT29 cells [1]. A significant increase in the number of G2/M phase cells in HT29 cells can also be induced by μM of pine stilbene [1]. Pinostilbene (20 μM, 40 μM; 24 h, 48 h) controls the expression of important signaling proteins linked to both apoptosis and cell growth [1]. In addition, pinosinbene functions as a methylated resveratrol derivative and shields SH-SY5Y cells from the neurotoxicity caused by 6-hydroxydopamine [2].
In vitro, pinostilbene exhibits cytotoxic effects against various cancer cell lines with differing potencies. It shows inhibitory effects on colon cancer cells. At 0.1-10 μM, pinostilbene reduces neurotoxicity in SH-SY5Y cells induced by the parkinsonian mimetic 6-hydroxydopamine. It reduces the release of lactate dehydrogenase and activity of caspase-3 triggered by 6-OHDA in a dose-dependent manner. Pinostilbene scavenges DPPH radicals with an IC50 of 47.1 μM. It inhibits CYP1B1 (IC50 = 2100 nM, Ki = 900 nM) and CYP1A1 (Ki = 120 nM). |
| ln Vivo |
In vivo, pinostilbene has been studied for its potential therapeutic effects in cancer and neurodegenerative diseases. As a metabolite of pterostilbene and a resveratrol derivative, it may share some of the in vivo benefits of these compounds, including antioxidant and anticancer activities. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile.
|
| Enzyme Assay |
Cell-free assays for pinostilbene involve evaluating its enzyme inhibitory activity and antioxidant properties. CYP1B1 and CYP1A1 inhibition is assessed using standard cytochrome P450 activity assays with fluorescent or luminescent substrates. Antioxidant activity is measured using DPPH radical scavenging assays. IC50 and Ki values are determined from dose-response curves. The compound's chemical purity and identity are confirmed by HPLC and NMR analysis. It is typically dissolved in DMSO or ethanol for assay preparation.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: HCT116 cells, HT29 cells Tested Concentrations: 24 hrs (hours), 48 hrs (hours) Incubation Duration: 0-100 μM Experimental Results: Inhibited the growth of two human colon cancer cells. Apoptosis analysis [1] Cell Types: HCT116 cells, HT29 cells Tested Concentrations: 20 μM, 40 μM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: resulted in a significant and dose-dependent increase in the percentage of cells in S phase. Cell viability assay [1] Cell Types: HCT116 Cell Tested Concentrations: 20 μM, 40 μM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: The expression levels of p53, Bax, cleaved caspase-3, cleaved PARP and p21Cip1/Waf1 increased Dramatically, At the same time, the expression levels of cyclin E and p-Rb were diminished. In vitro cellular assays for pinostilbene typically involve treating cancer cell lines or SH-SY5Y neuroblastoma cells with various concentrations of the compound. For neurotoxicity studies, cells are pre-treated with pinostilbene (0.1-10 μM) before exposure to 6-hydroxydopamine. Cell viability is assessed using MTT or LDH release assays. Apoptosis is evaluated using caspase-3 activity assays. JNK and c-Jun phosphorylation is assessed by western blotting. Dose-response curves are generated to determine IC50 values. |
| Animal Protocol |
In vivo animal studies for pinostilbene are conducted in models of cancer and neurodegenerative disease. The compound is administered via various routes including oral gavage or intraperitoneal injection. Tumor growth is monitored in cancer models. Neuroprotection is assessed in models of Parkinson's disease. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. Standard protocols for evaluating anticancer and neuroprotective agents would typically be employed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of pinostilbene include a molecular weight of 242.27 g/mol and molecular formula C15H14O3. As a natural product and metabolite of pterostilbene, it is expected to have moderate oral bioavailability and tissue penetration. The compound is typically stored at appropriate conditions as a research reagent. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of pinostilbene has not been extensively characterized in published literature. As a naturally occurring compound, it is generally considered to have a favorable safety profile at research doses. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans. Standard safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
3-Methoxy-4',5-Dihydroxy-trans-stilbene is a stilbene compound, a derivative of trans-resveratrol, in which one of the meta-hydroxyl groups is converted to the corresponding methyl ether. It is functionally related to trans-resveratrol. 3-Methoxy-4',5-Dihydroxy-trans-stilbene has been reported in soybean (Soymida febrifuga), Streptomyces avermitilis, and other organisms with relevant data.
Pinostilbene is a naturally occurring stilbenoid and major metabolite of pterostilbene. It exhibits cytotoxic effects against cancer cell lines and inhibits CYP1B1 (IC50 = 2100 nM, Ki = 900 nM) and CYP1A1 (Ki = 120 nM). Pinostilbene (0.1-10 μM) reduces 6-OHDA-induced neurotoxicity in SH-SY5Y cells and scavenges DPPH radicals (IC50 = 47.1 μM). It is a research tool for studying cancer, neuroprotection, and enzyme inhibition. |
| Molecular Formula |
C15H14O3
|
|---|---|
| Molecular Weight |
242.2699
|
| Exact Mass |
242.094
|
| CAS # |
42438-89-1
|
| PubChem CID |
5473050
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
454.3±33.0 °C at 760 mmHg
|
| Melting Point |
117-118℃
|
| Flash Point |
228.5±25.4 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.692
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
269
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1)O)/C=C/C2=CC=C(C=C2)O
|
| InChi Key |
KUWZXOMQXYWKBS-NSCUHMNNSA-N
|
| InChi Code |
InChI=1S/C15H14O3/c1-18-15-9-12(8-14(17)10-15)3-2-11-4-6-13(16)7-5-11/h2-10,16-17H,1H3/b3-2+
|
| Chemical Name |
3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~137.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1276 mL | 20.6381 mL | 41.2763 mL | |
| 5 mM | 0.8255 mL | 4.1276 mL | 8.2553 mL | |
| 10 mM | 0.4128 mL | 2.0638 mL | 4.1276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
